Sensex, Nifty slightly upbeat, midcaps to rule markets this week.
Vaccine major Bharat Biotech on Wednesday said its COVID-19 vaccine, Covaxin, has demonstrated an interim vaccine efficacy of 81 per cent in the Phase 3 clinical trials.
Sitharaman, a newcomer on the Forbes most powerful women list, is ranked 34th. The Forbes 2019 list of 'The World's 100 Most Powerful Women' has been topped by German Chancellor Angela Merkel, followed by President of the European Central Bank Christine Lagarde in the second spot and Speaker of the US House of Representatives Nancy Pelosi, ranked third. Also on the list is Bangladesh Prime Minister Sheikh Hasina (29).
Employees asked to work from home... cancelled travel plans... curtailed meetings... Caution and precaution dominate Corporate India's response to Covid-19.
The Oxford/AstraZeneca vaccine is also being produced as part of a tie-up by the Serum Institute of India.
Recently, Ranbaxy and Wockhardt too were hauled up.
The four ministers -- Tript Rajinder Singh Bajwa, Sukhbinder Singh Sarkaria, Sukhjinder Singh Randhawa and Charanjit Singh Channi -- and around two dozen legislators met in Chandigarh at the residence of Bajwa on Tuesday.
Ankleshwar plant is the third such facility to face action
NPPA's decision would also benefit domestic stent makers.
The central probe agency is looking at Kundra's purported dealings with Ranjeet Bindra and a firm called Bastian Hospitality in connection with this case.
While companies continue to face regulatory pressure leading to higher costs, they see an uptick from the launch of differentiated and high-margin products
Terming the judgement as a 'landmark judgement' in favour of poor patients, domestic drug manufacturer associations, including Indian Pharmaceutical Alliance and Indian Drug Manufacturers' Association, hailed the apex court's decision.
Sentiment also remained buoyant as a good monsoon season lifted hopes of a revival in farm output.
Only 11 antibiotics in clinical trials have received qualified infectious disease product status from the US FDA, of which five are Wockhardt's drugs.
Merck alleges violation of its patent for anti-diabetes drugs Januvia and Janumet.
The Delhi high court will hear on Monday a plea by leading Bollywood producers seeking to restrain Republic TV and Times Now from making or publishing allegedly "irresponsible, derogatory and defamatory remarks" against the film industry and conducting media trials against its members on various issues. The lawsuit by four Bollywood industry associations and 34 leading producers, which was filed on October 12, will come up for hearing before Justice Rajiv Shakdher.
With sales of over Rs 12,240 crore in nine months of the current financial year, it is ahead of Rs 11,580 crore recorded by Lupin but behind Sun Pharma, which reported Rs 19,350 crore sales.
The lawsuit, by four industry associations and 34 producers, seeks the court's direction to Republic TV, its editor-in-chief Arnab Goswami and reporter Pradeep Bhandari, Times Now, its editor-in-chief Rahul Shivshankar and group editor Navika Kumar and unknown defendants as well as social media platforms to refrain from making or publishing allegedly irresponsible, derogatory and defamatory remarks against Bollywood.
Daiichi won't remain a major shareholder in Sun Pharma.
Currently, the country is using two 'made-in India' jabs -- Covishield and Covaxin -- to inoculate its billion-plus population and has administered 20 crore doses since launching the world's largest vaccination drive in mid-January. A third vaccine, Russian-made Sputnik V, has been approved by the government and is being used on a smaller scale at present.
Since UK referendum outcome to exit European Union last Friday, 32 companies have hit record highs.
Increased price control over branded generic medicines has affected its profitability
Prodded by patent cliff & increasing competition, it files application for foray into injectible oncology segment.
As its factories resumed operations after over two-month of grim battle against coronavirus, China is busy tapping into the vast business opportunities of export of key medical goods, specially ventilators and personal protection equipment (PPE), across the world, including India, where both private and government bodies are placing orders for the import of these products.
Prosecutors unveiled charges against Valvani alleging he fraudulently made $25 million by getting advance information about US Food and Drug Administration approvals of generic drug applications
The numbers are the highest ever in the history of domestic drug discovery initiatives triggered by companies such as Dr Reddy's and Ranbaxy over a decade ago.
Sun Pharma open to large acquisitions post Ranbaxy.
India's first mRNA platform-based vaccine will remain stable at 2-8 degrees Celsius while Pfizer-BioNTech's vaccine needs minus 70 degrees Celsius and Moderna vaccine can remain stable for six months at minus 20 degrees Celsius, reports Sohini Das.
Entirely new businesses have been built using data to disrupt traditional companies.
Murthy, 43, who originally hails from Karnataka, was appointed America's 19th Surgeon General by then president Barack Obama in 2014.
Drug majors Pfizer and Abbott stopped sale of their popular cough syrups Corex and Phensedyl respectively.
It had not been able to meet the deadline so far, though investigation into the matter was over, sources said.
The health ministry has formed a committee to consider raising the number of drugs deemed essential and subject to price caps.
'He is worried about how best the Punjab crisis can be resolved.'
Despite the ongoing trouble India's largest drug maker, Ranbaxy, is facing in the United States, domestic pharmaceutical companies are betting high on the world's largest drug market with added vigour.
Axis Bank was the top gainer in the Sensex pack, surging over 13 per cent, followed by ICICI Bank, IndusInd Bank, Maruti, TCS, Kotak Bank and Reliance Industries. On the other hand, Nestle India, HUL, Tech Mahindra and Sun Pharma ended in the red. NSE Nifty zoomed 273.95 points, or 3.03 per cent, to finish at 9,266.75.
The FDA issued the letter on October 15, and has given the company 15 days to respond.
The development assumes significance as on Monday the Supreme Court had rejected the plea of Novartis AG for patent protection of its anti-cancer drug Glivec.
Company aims to build five Rs 100 cr-plus brands and launch products from South African arm in domestic market
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances